Skye Bioscience, Inc. Stock (EMBI) - Quote Nasdaq- MarketScreener (2024)

SKYE BIOSCIENCE, INC.

Add to a list

To use this feature you must be a member

Log inSign up

Equities

EMBI

US83086J2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
13 ^USD	+0.70%		+35.56%	+377.94%

Apr. 12	Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	CI
Mar. 22	Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Financials (USD)

Sales 2024 *	-	Sales 2025 *	-	Capitalization	362M
Net income 2024 *	-23M	Net income 2025 *	-34M	EV / Sales 2024 *	-
Net cash position 2024 *	-	Net cash position 2025 *	-	EV / Sales 2025 *	-
P/E ratio 2024 *	-16.4x	P/E ratio 2025 *	-14.8x	Employees	11
Yield 2024 *	-	Yield 2025 *	-	Free-Float	92.92%

Chart Skye Bioscience, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Skye Bioscience, Inc.

Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	Apr. 11	CI
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating	Mar. 14	MT
Skye Bioscience, Inc. announced that it has received $40 million in funding	Mar. 12	CI
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	Mar. 10	CI
Skye Bioscience Announces Board Changes	Mar. 04	CI
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26	CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	Feb. 11	CI
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	Jan. 28	CI
Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	Dec. 11	CI
Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Skye Bioscience, Inc. Announces Board Appointments	23-09-01	CI
Skye Bioscience, Inc. acquired Bird Rock Bio, Inc. for $15.6 million.	23-08-20	CI
Skye Bioscience, Inc. announced that it has received $12 million in funding	23-08-17	CI
Skye Bioscience, Inc. announced that it expects to receive $12 million in funding	23-08-14	CI

More news

Analyst Recommendations on Skye Bioscience, Inc.

Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating

Mar. 14

More recommendations

Press releases Skye Bioscience, Inc.

Skye Bioscience Uplists to The Nasdaq Global Market	Apr. 10	AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	Apr. 03	PU
Skye Bioscience Announces $40 Million Private Placement Equity Financing	Mar. 11	NE
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	Mar. 04	AQ
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26	AQ

More press releases

Quotes and Performance

1 day	+0.50%
1 week	+34.62%
Current month	-17.46%
1 month	-2.27%
3 months	+383.52%
6 months	+378.15%
Current year	+374.63%

More quotes

Highs and lows

1 week

8.25

14.20

1 month

7.35

15.78

Current year

Managers and Directors - Skye Bioscience, Inc.

Managers	Title	Age	Since
Punit Dhillon CEO	Chief Executive Officer	44	18-01-18
Kaitlyn Arsenault DFI	Director of Finance/CFO	-	21-10-04
Christopher G. Twitty CTO	Chief Tech/Sci/R&D Officer	52	22-12-12

Members of the board	Title	Age	Since
Margaret Dalesandro BRD	Director/Board Member	77	20-08-06
Praveen Tyle BRD	Director/Board Member	64	21-07-21
Andrew Schwab BRD	Director/Board Member	53	23-08-17

More insiders

Quotes

Date	Price	Change	Volume
24-04-15	13	+0.70%	53,715
24-04-12	12.91	+1.73%	51,807
24-04-11	12.69	-0.94%	17,581
24-04-10	12.81	+39.69%	23,348
24-04-09	9.17	-4.38%	26,811

Delayed Quote Nasdaq, April 15, 2024 at 09:34 am EDT

More quotes

Company Profile

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Sector

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.91USD

Average target price

22.5USD

Spread / Average Target

+74.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

	1st Jan change	Capi.
SKYE BIOSCIENCE, INC.	+374.63%	362M
IQVIA HOLDINGS INC.	+1.67%	42.63B
LONZA GROUP AG	+52.05%	42.32B
MODERNA, INC.	+5.62%	40.26B
CELLTRION, INC.	-9.58%	27.27B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.24B
ALNYLAM PHARMACEUTICALS, INC.	-22.82%	18.78B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.67%	12.39B
MEDPACE HOLDINGS, INC.	+29.40%	12.24B
UNITED THERAPEUTICS CORPORATION	+6.74%	10.95B

Stock Market
Equities
EMBI Stock

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019 Replicate our performance

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '111314073');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });